课题基金 / 基金详情

RNA Silencing in the Oral Cavity

RNA Silencing in the Oral Cavity
口腔中的 RNA 沉默
批准号:
7531996
负责人:
Andrew George Jakymiw
金额:
$9.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-01 至 2010-08-31

项目摘要

项目成果

Andrew George Jakymiw的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):最近,我们的实验室已经证明,GW182蛋白的细胞质焦点被称为GW小体(GWB),与一种进化上保守的机制有关,该机制涉及基因转录后沉默,称为RNA干扰(RNAi)。RNAi是一种细胞过程,正在给基因功能研究带来革命性的变化,使用RNAi进行治疗是相当令人兴奋的。目前,我们的实验室正致力于进一步深入GW182和GWB功能的生物学研究,目的是确定GWB在RNAi过程的激活中的作用及其在调节靶外效应中的作用。通过进一步了解GWB的生物学功能,这将转化为基于RNAi治疗的改进药物设计。尽管越来越多的报告显示了RNAi的许多令人兴奋的治疗方面,但关于RNAi在口腔疾病治疗中的应用的文章数量有限。因此,中国人民解放军S的当前目标是在从指导阶段过渡到独立科学研究人员的过程中,通过将基于RNAi的治疗方法引入口腔医学来解决这一问题。长期的职业目标是在口腔健康和基于RNAi的治疗领域确立自己的专家地位。一个主要的优点是口腔粘膜易于操作,可能特别适合基于RNAi的治疗。因此,首席研究人员计划在佛罗里达大学牙科学院继续接受口腔生物学领域的培训,特别是口腔癌症研究领域的培训。在该奖项的指导阶段,首席研究员将描述口腔癌细胞中RNAi的功能,并优化体外和体内的药物和病毒基因输送技术。此外,首席研究员将使用RNAi在体外识别和靶向潜在的促癌基因靶点。在该奖项的独立阶段,首席研究人员建议确定使用基于RNAi的药物和基因治疗方法来治疗人类肿瘤小鼠模型的可行性。这项建议的长期研究目标是开发这项新技术,并将其开发成口腔癌的有效治疗方法。通过将RNAi用于口腔医学,它将使科学家和临床医生都能压制口腔疾病。我们建议的研究结果可能会对使用基于RNAi的疗法治疗其他疾病产生更广泛的影响。
英文摘要
DESCRIPTION (provided by applicant): Recently, our laboratory has demonstrated that cytoplasmic foci termed GW bodies (GWBs) for the GW182 protein they harbor are linked to an evolutionarily conserved mechanism involved in the post-transcriptional silencing of genes, referred to as RNA interference (RNAi). RNAi is a cellular process that is revolutionizing gene function studies and there is considerable excitement about using RNAi for therapy. Currently, our lab is focused on furthering the biological study of GW182 and GWB function, with the goal to ascertain the role of GWBs in the activation of the RNAi process and their contribution to regulating off-target effects. By furthering our understanding of the biological functions of GWBs, this should translate into improved drug designs for RNAi-based treatments. Despite the growing number of reports demonstrating the many exciting therapeutic aspects of RNAi, only a limited number of articles have been published regarding the application of RNAi in the treatment of oral diseases. It is therefore, the P.l.'s immediate goal to address this concern by bringing RNAi-based treatments to oral medicine during his transition from a mentored stage to becoming an independent scientific investigator. The long-term career objective is to establish himself as an expert in the field of oral health and RNAi-based therapies. A major advantage is that the oral mucosa is readily accessible to manipulation and may be especially suitable for RNAi-based treatments. It is therefore the principal investigator's plan to further his training in the field of oral biology at the University of Florida College of Dentistry, in particular in the field of oral cancer research. During the mentored phase of the award the principal investigator will characterize RNAi function in oral cancer cells, and optimize drug and viral gene delivery techniques in vitro and in vivo. Furthermore, the principal investigator will identify and target potential cancer-promoting gene targets in vitro using RNAi. During the independent phase of the award the principal investigator proposes to detemine the feasability of using RNAi-based drug and gene therapy approaches to treat a human tumor mouse model. The long-term research goal of this proposal is to exploit this novel technology and develop it into an effective therapy for oral cancer. By harnessing RNAi for oral medicine it will allow both scientists and clinicians to silence diseases of the oral cavity. Results from our proposed studies may have a broader impact applicable to treatment of other diseases using RNAi-based therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Stereochemical and dual peptide siRNA-carrier complexes for oral cancer therapy
CHARACTERIZATION OF DICER MRNA VARIANTS IN ORAL CANCER
RNA Silencing in the Oral Cavity
RNA Silencing in the Oral Cavity
海外基金